SOC Telemed
soc company overview | SOC Telemed
Company
Deck Type
Deck date
January 2022
Slide
4 of 27
Related slides by other companies
Overstock
Results
April 2021
easy delivery support | Overstock
Nuvalent
Investor Presentation
January 2024
potential best in class profile for alk opportunity to both move up the treatment paradigm grow the market with deep durable responses no clear standard of care soc current soc compound mutations disease single mutations disease current soc of disease demonstrated activity where current available therapies have failed opportunity to differentiate with deep durable responses and clinical activity observed in heavily patients who likely exhausted all available therapies with single and compound mutations with history of metastasis including intracranial responses sparing clinical activity observed in patients with single and compound resistance mutations clinical activity observed in patients who are naive favorable overall preliminary safety consistent with avoiding related head to head clinical studies comparing with currently approved or investigational therapies have not been conducted sources sales and forecasts accessed and lung cancer jama shaw and no peters shaw lancet jack cancer res lin package inserts and | Nuvalent
Recursion Pharmaceuticals
Investor Day
January 2023
clinical phase studies well tolerated with no dose dependent adverse events in sad and mad mad study placebo further confidence confirming safety | Recursion Pharmaceuticals
Omnicell
Investor Presentation
October 2023
backlog million product backlog total backlog long term product backlog long term advanced services backlog total backlog | Omnicell
Other recent decks by SOC Telemed
See all presentations (2 decks)
Investor Day
September 2020
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights